Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 6/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.49 |
| ▸ | HTR3B | O95264 | 3/20 | 0.49 |
| ▸ | HTR3A | P46098 | 3/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14138617 | 0.85 | HTR6 (0.49) | ALDH1A1LMNAKDM4EHTR6MAPT | |
| SCHEMBL18698646 | 0.84 | MAPT (0.60) | ALDH1A1LMNASMN1; SMN2GAAMAPT | |
| SCHEMBL18553764 | 0.83 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EHTR6ADRB1 | |
| SCHEMBL2626629 | 0.81 | HTR6 (0.65) | HTR6ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL18553740 | 0.81 | KDM4E (0.56) | ALDH1A1LMNAKDM4EHTR6ADRB1 | |
| SCHEMBL532144 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EHTR6ADRB1 | |
| SCHEMBL2626578 | 0.80 | GHSR (0.48) | ALDH1A1LMNAKDM4EHTR6SMN1; SMN2 | |
| SCHEMBL2626579 | 0.80 | GHSR (0.48) | ALDH1A1LMNAKDM4EHTR6SMN1; SMN2 | |
| SCHEMBL17893595 | 0.80 | SMN1; SMN2 (0.47) | ALDH1A1LMNASMN1; SMN2GAAMAPT | |
| SCHEMBL18553788 | 0.80 | KDM4E (0.58) | ALDH1A1LMNAKDM4EHTR6ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051324-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | KEYTHERA (SUZHOU) BIO-PHARMACEUTICALS CO., LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4450498-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Keythera (Suzhou) Bio-Pharmaceuticals Co., Limited (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-118382624-A | PARP inhibitors, pharmaceutical compositions comprising the same and uses thereof | 凯复(苏州)生物医药有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023109521-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109521-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2022-02-17 | — | — | US | disclosed |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10568882-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | ALDH1A1 734/4885LMNA 267/4885KDM4E 1974/4885 |
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885LMNA 328/4885KDM4E 1841/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | ALDH1A1 1645/4885LMNA 2366/4885KDM4E 2958/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | ALDH1A1 2531/4885LMNA 3348/4885KDM4E 1801/4885 |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885LMNA 328/4885KDM4E 1841/4885 |
| US-20250051324-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PARP1, PARP2, PARP11 | ALDH1A1 901/4885LMNA 335/4885KDM4E 1035/4885 |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885LMNA 328/4885KDM4E 1841/4885 |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885LMNA 328/4885KDM4E 1841/4885 |
| US-10568882-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885LMNA 328/4885KDM4E 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.